-
EP3433251
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3433251
| EP3433251 - CINNOLIN-4-AMINE COMPOUNDS AND THEIR USE IN TREATING CANCER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 07.02.2020 Database last updated on 31.08.2024 | |
| Former | Request for examination was made Status updated on 30.12.2018 | ||
| Former | The international publication has been made Status updated on 29.09.2017 | ||
| Former | unknown Status updated on 29.03.2017 | Most recent event Tooltip | 07.02.2020 | Application deemed to be withdrawn | published on 11.03.2020 [2020/11] | Applicant(s) | For all designated states Astrazeneca AB 151 85 Södertälje / SE | [2019/05] | Inventor(s) | 01 /
PIKE, Kurt, Gordon AstraZeneca Hodgkin Building Chesterford Research Park Little Chesterford Essex CB10 1XL / GB | 02 /
BARLAAM, Bernard, Christophe AstraZeneca Darwin Building Cambridge Science Park Milton Road Cambridge Cambridgeshire CB4 0WG / GB | [2019/05] | Representative(s) | AstraZeneca Intellectual Property Eastbrook House Shaftesbury Road Cambridge CB2 8BF / GB | [N/P] |
| Former [2019/05] | AstraZeneca Milstein Building Granta Park Cambridge CB21 6GH / GB | Application number, filing date | 17712123.3 | 20.03.2017 | [2019/05] | WO2017EP56592 | Priority number, date | US201662310883P | 21.03.2016 Original published format: US 201662310883 P | [2019/05] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017162605 | Date: | 28.09.2017 | Language: | EN | [2017/39] | Type: | A1 Application with search report | No.: | EP3433251 | Date: | 30.01.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.09.2017 takes the place of the publication of the European patent application. | [2019/05] | Search report(s) | International search report - published on: | EP | 28.09.2017 | Classification | IPC: | C07D405/14, A61K31/502, A61P35/00 | [2019/05] | CPC: |
A61K31/502 (EP,KR,US);
C07D405/14 (EP,KR,US);
A61P35/00 (EP,KR,US);
A61K31/175 (EP,US);
A61K31/195 (EP,US);
A61K31/40 (EP,US);
A61K31/4184 (EP,US);
A61K31/4745 (EP,US);
A61K31/675 (EP,US);
A61K31/704 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/05] | Extension states | BA | 22.10.2018 | ME | 22.10.2018 | Validation states | MA | 22.10.2018 | Title | German: | CINNOLIN-4-AMIN-VERBINDUNGEN UND DEREN VERWENDUNG ZUR BEHANDLUNG VON KREBS | [2019/05] | English: | CINNOLIN-4-AMINE COMPOUNDS AND THEIR USE IN TREATING CANCER | [2019/05] | French: | COMPOSÉS CINNOLIN-4-AMINE ET LEUR UTILISATION POUR TRAITER LE CANCER | [2019/05] | Entry into regional phase | 22.10.2018 | National basic fee paid | 22.10.2018 | Designation fee(s) paid | 22.10.2018 | Examination fee paid | Examination procedure | 05.10.2018 | Amendment by applicant (claims and/or description) | 22.10.2018 | Examination requested [2019/05] | 22.10.2018 | Date on which the examining division has become responsible | 14.05.2019 | Loss of particular rights, legal effect: Claims | 17.06.2019 | Despatch of communication of loss of particular rights: Claims {1} | 01.10.2019 | Application deemed to be withdrawn, date of legal effect [2020/11] | 29.10.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2020/11] | Fees paid | Penalty fee | Additional fee for renewal fee | 31.03.2019 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2008090353 (ASTRAZENECA AB [SE], et al) [A] 1-15 * claims 1, 2, 8, 10, 12 *; | [A]WO2012162254 (ELAN PHARM INC [US], et al) [A] 1-15 * paragraphs [0123] , [ 158]; claims 1, 23; compound 126 *; | [A]WO2015170081 (ASTRAZENECA AB [SE], et al) [A] 1-15 * examples 1, 13, 30, 36, 37, 39, 40; claims 1, 8, 9-15; table 2 *; | [AP] - DEGORCE ET AL, "Discovery of novel 3-quinoline carboxamides as potent, selective and orally bioavailable inhibitors of Atexia Telangiectasia mutated (ATM) kinase", JOURNAL OF MEDICINAL CHEMISTRY,, (20160603), vol. 59, pages 6281 - 6292, XP002762230 [AP] 1-15 * compounds 20, 21, 72 * | by applicant | WO9722596 | WO9730035 | WO9732856 | WO9813354 | WO2012101062 |